RenovoRx 2025 net loss widens on higher operating expenses

ReutersMar 30, 2026 8:25 PM

Overview

US oncology device maker's 2025 revenue rose to $1.1 mln in first full commercial year
Net loss widened to $11.2 mln as operating expenses increased with commercial and R&D investments
Company ended 2025 with $7 mln cash

Outlook

Company expects to complete TIGeR-PaC trial enrollment by mid-2026, with final data in 2027
RenovoRx plans to drive commercial growth for RenovoCath in 2026 and beyond

Result Drivers

PHYSICIAN ADOPTION - Co said revenue growth in 2025 was driven by initial physician adoption and demand at active commercial cancer centers
COMMERCIAL INFRASTRUCTURE - Co attributed higher operating expenses to buildout of commercial infrastructure, including sales and marketing capabilities

Company press release: ID:nGNX2674pG

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
FY Net Income		-$11.2 mln
FY Basic EPS		-$0.32
FY Operating Expenses		$13.3 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 386.7% above its March 27 closing price of $1.13

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

Bitcoin Price Analysis: What Is to Stop BTC from Making Another Run at All-Time Highs in 2026?

This strategic analysis covers institutional BTC price targets from JPMorgan and Fidelity, the impact of the U.S. Strategic Reserve, and whether the four-year cycle is broken. Stay updated on BTC to USD trends and key market risks.

USD/JPY Hits 160.00 Mark, Will Japanese Government Intervene? Will the Currency’s Rally Be Contained?

TradingKey - As of March 30, USD/JPY continued to fluctuate at high levels near the 160 mark, with the Yen falling to a nearly one-year low. Market expectations for potential intervention by Japanese authorities have intensified rapidly, while uncertainty surrounding the Bank of Japan's policy path

Tesla (TSLA) 2026 Deep Dive Report: Behind the 5x Pricing Divergence, a Sunset Automaker or AI Giant?

An in-depth analysis of Tesla’s 2026 investment outlook, exploring the transformation into an AI giant and Robotaxi mass production plans behind Wall Street’s five-fold valuation gap. Through a comprehensive deconstruction of gross margin data, the energy business, and macro interest rate risks, we reveal the key investment signals and valuation reality for Tesla in 2026.

Memory Crashes. Memory Stocks Suffer Collective Unexpected Pullback, Is Memory Bull Cycle Ending or a Buying Opportunity?

TradingKey - Since mid-March, a pivot in memory prices has sparked market concerns that the memory cycle may have peaked. As of Friday Eastern Time, memory chip stocks in the US market experienced a sharp weekly pullback. Western Digital (SanDisk), which previously recorded the highest gains and strongest elasticity, fell over 13% from its peak during the week; Micron dropped more than 15% from its high. The sector saw a collective weekly correction, leading the decline of the Nasdaq Index.

What Is Google TurboQuant Compression Algorithm? How Does It Affect the AI Memory Chip Industry?

TradingKey - Google’s (GOOGL) (GOOG) introduction of the TurboQuant vector compression algorithm has sent shockwaves through the AI memory chip industry, acting like a precisely cast stone.

Tradingkey

KeyAI

